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The objective of this studywas to evaluate the acceptability of an alimentary supplement of bovinewhey-protein concentrate (WPC)
and TGF-𝛽, unavailable commercially, by patients with Crohn’s disease (CD) and determine the chemical composition, solubility,
and total amino acids content.The supplement was diluted in water, and an acceptance test was done to evaluate the aroma, flavour,
and viscosity of the product using facial hedonic scale (nine-point scale), applied on 54 CD patients. The supplement composition
indicated 73.3% protein, 10.5% fat, 2.2% ash, 6.3% water, and 7.7% carbohydrate. The supplement is presented as a good protein
source and high content of essential amino acids. The average acceptance for all the attributes was between 5.0 and 6.0, and the
flavour was mainly associated with soybean/grain, sour milk, and sweet/vanilla flavour. The results indicated that the supplement
provided important nutritional properties for CD patients; however, for a large number of individuals to be encouraged to perform
supplementation, it is essential to improve the sensory quality of the product. In order to do so, additional research is necessary to
prevent the formation of volatiles which cause off-flavours or to mask undesirable aromas/flavours found in it.
1. Introduction
The interest in whey-protein supplement (WPS) increased
with consumer’s sensibility concerning health benefits, since
the immunomodulatory role of WPS has already been
amply demonstrated [1, 2]. The whey protein (WP) con-
stitutes 20% of the total protein content of bovine milk
and includes alpha-lactalbumin (𝛼-LA), beta-lactoglobulin
(𝛽-LG), bovine serum albumin (BSA), lactoferrin (LTF),
immunoglobulins (Ig), and growth factors to tissues. They
are associated with the prebiotic effect, promoting tissue
restoration, maintenance of intestinal integrity, destruction
of pathogens, and elimination of toxins [3]. Highly digestible
and quickly absorbed by the body, theWPs are widely used in
situations of metabolic stress [4]. Whey-protein concentrates
(WPCs) and whey-protein isolates (WPIs) usually contain a
cysteine concentration at least four times higher than other
high-quality proteins, and it produces an improvement in
immune response [5].
Crohn’s disease (CD) is a complex chronic inflammatory
disease, with periods of exacerbation [6], which affects the
gastrointestinal tract, andmay also involve themusculoskele-
tal system, skin, and eyes [7]. It is important to consider
that although the CD may affect any portion of the digestive
tract, in most cases it occurs more frequently in the small
intestine. The ileum and cecum are affected in 40% of cases,
the small intestine in 30%, and colon in 25% [8]. With this
large percentage of presentation in the small intestine, the
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Figure 1: Facial hedonic scale used in the present study [19].
disease can be extremely harmful to the nutritional status of
patients.
The deregulation of the immune system associated with
the intestinal mucosa leads to chronic inflammation, which
leads to the destruction of intestinal epithelium and severe
functional abnormalities, with loss of absorptive capacity
and excessive secretion of electrolytes and intestinal fluids.
Thus, CD individuals may show nutritional changes ranging
from deficiency of trace elements to severe malnutrition [9].
Several types of diets and supplements are able to modulate
the immune system functions, and their bioactive compo-
nents have been proposed to form the basis of functional
immunomodulatory food product [10]. Human and bovine
milk contains the transforming growth factor 𝛽 (TGF-𝛽),
multifunctional polypeptide with an important role in the
development of tolerance and prevention of autoimmunity
[11]. Despite the valuable functional and nutritional proper-
ties, it is important to note thatWPhas little or no flavour [12].
However, some compounds inwhey are susceptible to chemi-
cal reactions, for example, lipid oxidation forming unpleasant
aromas and flavours in the product [13, 14]. Today, consumers
increasingly expect to obtain pleasure from food and require
sensory characteristics, for example, aroma, flavour, texture,
and, along with these sensory characteristics, maintaining
or improving their health and welfare. Therefore, for CD
patients (who often require specific nutritional support)
to be encouraged to undertake the process of continuous
alimentary supplementation, it is necessary to study the
acceptability of the product, so that researchers and industries
can adapt to the sensory quality of the product as expected by
patients.
Thus, the objective of this study was to evaluate the
acceptability of an alimentary supplement of whey-protein
concentrate (WPC) andTGF-𝛽, unavailable commercially, by
patients with Crohn’s disease. It is the first time that a study
about the acceptability of this supplement by CD patients is
done. In this study the chemical composition, solubility and
total amino acids content were also determined.
2. Material and Methods
2.1. Material. The supplement used was donated by an
industry of cheese andwhey products fromCalifornia (USA).
The supplement was constituted bywhey-protein concentrate
(WPC) with the addition of TGF-𝛽 in the exogenous shape,
but in amounts not reported by the company, since it is a
supplement not marketed yet.
2.2. Chemical Composition of the Supplement. The humidity,
total solids, ash, and protein were established based on
the methods of AOAC [15]. Total lipids were determined
according to Bligh andDyer [16] and total carbohydrateswere
estimated by difference, subtracting the sum of the values
obtained in other measurements of 100%.
2.3. Protein Solubility. The water protein solubility (%) was
determined according to the method of Morr and Foegeding
[17]. The effects of different pH (from 2.5 to 7.5) were also
evaluated.
2.4. Total Amino Acid Determination. Total amino acids in
the supplement were determined by reversed phase liquid
chromatography, after acid hydrolysis (24 h), plus 20% ofHCl
phenol, followed by derivatisation with phenylisothiocyanate
[18].
2.5. Recruiting and Selecting Individuals. Fifty-four individ-
uals (24 male and 30 female) who had CD and aged from
18 to 62 years (median age of 37 years) were invited to
participate in this study. It was conducted in the Gastrocentro
(Centre for Diagnosis of Digestive Tract Diseases), University
of Campinas (UNICAMP), Brazil. The patients with CD
performed the acceptance test of the supplement in a single
session for the three attributes: aroma, flavour, and viscosity,
according to the following criteria: (a) patients of both
genders; (b) attending outpatient department regularly.
This study was approved by the local ethics committee
under protocol 304/2007, and all individuals signed an
informed consent form before the sensory evaluation.
2.6. Preparing the Samples. Thepatients conducted an accep-
tance test assessing the supplement in Inflammatory Intesti-
nal Disease Outpatient Clinic at Gastrocentro (UNICAMP).
Such test was previously prepared by diluting 15 g of the
product in 100mL of filtered water at room temperature.
The test was performed in individual booths and during the
morning from 9 : 00 to 11 : 00 h.
2.7. Sensory Analysis. The CD patients assessed in a sin-
gle session the acceptance of the product concerning the
attributes: aroma, flavor, and viscosity by using nine-point
facial hedonic scale in the extreme left and extreme right,
under the term “terrible” and the term “great,” as shown in
Figure 1 [19, 20].
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Table 1: Chemical composition of the supplement.
Protein (%) 1,2 Fat (%)1,2 Ash (%)1,2 Water (%)1,2 Carbohydrate (%)2,3
73.30 ± 0.43 10.48 ± 0.03 2.15 ± 0.33 6.36 ± 0.01 7.71 ± 0.01
1Values according to averages (±SD) of three determinations. 2Values expressed on dry basis.
3Calculated by difference = 100 − (total protein + fat + ash + water).
Table 2: Total amino acids content in the supplement.
Amino Acids (g/100 g of protein)
Aspartic acid 10.16
Glutamic acid 16.95
Serina 5.18
Glycine 2.00
Histidine 1.79
Arginine 1.44
Threonine 6.22
Alanine 5.00
Proline 5.90
Phenylalanine and tyrosine 5.47
Valine 5.64
Methionine and cystine 3.10
Cysteine 2.01
Isoleucine 6.49
Leucine 10.16
Lysine 9.32
Tryptophan ∗
∗nondetermined.
To evaluate the acceptance results, the items of hedonic
facial scale were converted into numerical values. Thus, the
term “terrible” was converted into the number 1, the term
“very bad” was converted into the number 2, the term “bad”
into the number 3, and so on, until the term “great,” that was
converted to number 9 in the scale.
For aroma and flavour, the patients were also asked to
quote the aromatic notes and flavours perceived in the sup-
plement sample and to assess the product purchase intention.
2.8. Statistical Analysis. The physicochemical data were as-
sessed by calculating the average, standard deviation, and
Tukey’s test, by using the software SPSS 15.1 forWindows [21].
Sensory analysis data were assessed by calculating average,
and perceived percentage of quotes for aroma and flavours,
processed in the Microsoft Excel 2002.
3. Results and Discussion
3.1. Physicochemical Characterization of The Supplement.
Table 1 shows the supplement chemical composition used
in this study. In its composition, the supplement had high
protein value and low carbohydrate content.
Due to the high content of essential amino acids, espe-
cially the branched chain ones, the supplement also showed
high nutritional value, as noted in Table 2. These values
are above average when compared to those from other
Table 3: Solubility of the supplement in water.
pH Supplement solubility (%)1,2
2.5 71.56 ± 1.45C
3.5 80.93 ± 0.53A
4.5 77.54 ± 0.11B
5.5 80.71 ± 0.28A
6.5 81.18 ± 0.56A
7.5 79.88 ± 0.72A
1Values for averages (±SD) of three determinations.
2Values with different letters mean significant difference, according to
Tukey’s test (𝑃 < 0.05).
Table 4: Acceptance averages of aroma, flavour, and viscosity (𝑛 =
54 patients).
Attributes Acceptance∗
Aroma 5.3
Flavour 5.5
Viscosity 5.5
∗Values on the scale: 1 = terrible; 5 = maybe good or maybe bad; 9 = great.
protein sources, for example, casein, soybean, egg, rice, beans,
chicken, and so forth, providing supplement with important
nutritional properties. It may contribute to maintain the
nutritional status for CD patients, who often require special
nutritional support.
Due to the WPC amino acids profile, this protein is used
to formulate several specialty products, for example, infantile
formulas, and for the performance of muscle metabolism,
due to the high content of essential amino acids branched
chain, for example, leucine and isoleucine [22]. These char-
acteristics are hugely important for CD patients, due to
hypermetabolism and progressive loss of lean mass, with the
clinical evolution of the disease.
The results indicated that the supplement has good
solubility in a wide pH range (Table 3), which is quite
advantageous, since it may be used to formulate various
foods, for example, fermented beverages, ice creams, and so
forth [23].Thus, it increases the possibilities for consumption
of this supplement with high nutritional value.
3.2. Sensory Evaluation. According to the acceptance aver-
ages for aroma, flavour, and viscosity obtained for the CD
patients, it was observed that the assessment of the sup-
plement in general was between the terms “maybe good or
maybe bad” and “just a little good” (Table 4).
According to the frequency of responses to aroma, 46.3%
of values were in the region of product rejection (values
from 1 to 4 or between the words “terrible” and “just a little
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Figure 2: Distributing patients according to the hedonic values to
accept the aroma, flavour, and viscosity, provided to the supplement.
Hedonic values∗ 1 = terrible, 5 = maybe good or maybe bad, and 9 =
great.
bad”). By contrast, 25.9% of the assessed individuals classified
the supplement as “maybe good or maybe bad” and 28% of
patients assessed the supplement between “just a little good”
and “great” (values between 6 and 9 on the scale) (Figure 2).
In fact, the supplement aroma was characterised by
presenting the unpleasant aroma notes in percentage of
responses, such as soybean/grain (31%), sour milk (17%),
and cooked food (9%). It was observed that a small pro-
portion of quotes were associated with pleasant aromas,
for example, sweet/vanilla (17%). Concerning the flavour,
the frequency of responses was quite similar to the aroma:
nearly 28% of patients liked the product and 50% did not
like it. Additionally, the flavour was mainly associated with
soybean/grain flavour (34% of respondents), sour milk (16%
of respondents), sweet/vanilla (13%), and milk powder (9%)
(Table 5). For viscosity, the acceptance was a little better;
nearly 40% liked the sample viscosity against 33% who did
not like it.
In general, it was observed that roughly 30% of individ-
uals liked the supplement concerning all attributes assessed.
By contrast, half of them did not like it and the other, from
20% to 25%, classified it as “maybe good or maybe bad.” It
indicates that the product needs to be improved, especially
its aroma and flavour. On the other hand, the acceptance was
not as bad as the supplement was evaluated only dissolved in
water, maybe if the supplement was added to fruit juice or
milk drink could have a better acceptance by the patients.
The aroma and flavour of grain/soybean, sourmilk, bitter,
cheese, cooked food, all noticed by individuals, can be from
lipid oxidation orMaillard reaction (or both), as some studies
have shown. These reactions contribute to the formation of
off-flavours and to the loss of pleasant aromas/flavours of
whey-protein concentrate, thus limiting its use [24]. Quach
et al. [25] by headspace-SPME (solid-phase microextraction)
isolated and identified 43 volatile from WPC, among them
several aldehydes, ketones, and hydrocarbons. According to
the authors, several of them can contribute to the aromas
and flavours perceived inWPC, for example, 2-heptanone, 2-
nonanone, 1-octen-3-ol, and volatiles associated with aromas
of cardboard, metal, and mould, respectively.
Table 5: Citation frequency (%) of perceived aroma notes and
perceived flavours by individuals in the supplement (𝑛 = 54
patients).
Descriptor Aroma (%) Flavour (%)
Grain/soybean 31 34
Sour milk 17 16
Sweet/vanilla 17 13
Cooked food 9 7
Milk powder 8 9
Cheese 8 1
Vomit 4 7
Metallic 4 6
Earth 2 4
Bitter 0 3
The formation of volatiles during production and storage
of WPC is difficult to control, considering all the reactions
that may occur. To obtain a WPC with milder aroma/flavour
would be necessary to standardise the conditions for process-
ing and storage of WPC, and thus obtain a supplement with
better sensory quality.
Despite the low acceptance of the product, 28%of patients
indicated that they “probably would buy” the supplement,
and 22% said they “definitely would buy” the product. Such
fact indicates a good purchase intention. By contrast, 19%
of patients indicated that they “perhaps would or would not
buy” the supplement, 22% said they “probablywould not buy”
the product, and 9% of them “definitely would not buy”.
Several studies have demonstrated that complete nutri-
tion with protein supplements improves nutritional status
of patients, intestinal inflammation, and, often, recovery of
intestinal mucosa [26]. Paradoxically, the treatment using
only corticosteroids presents limited effects on the mucosa
[27]. In children affected by CD, complete nutrition plays a
fundamental role in the increase of their growth, since the
additional nutrient provision is coupled with improvement
in intestinal inflammation [26]. In CD-acute adults, the
complete nutrition is greatly effective in relieving the disease
and in the nutritional status of individuals, and it can be used
together to other therapies to control CD [28]. Therefore,
studies assessing and developing oral solutions that are better
accepted by patients are very important.
4. Conclusion
The supplement presented as a good protein source and
high content of essential amino acids providing important
nutritional properties that can contribute to maintain the
nutritional status for CD patients, who often require special
nutritional support.
Although the supplement was not well accepted for
aroma, flavour, and viscosity by most patients, almost 30%
of individuals liked the supplement concerning all attributes
assessed. The results indicated that the supplement provided
important nutritional properties for patients with CD; how-
ever, for a large number of patients to be encouraged to start
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the supplementation process, it is essential to improve the
sensory quality of the product.
In order to do so, additional research is necessary to
prevent the formation of volatiles, which cause off-flavours
in WPC, associated in the present study with soybean/grain,
sour milk, cooked food, vomit, and other undesirable aromas
and flavours.
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